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Background: Asymptomatic cognitive impairment in human immunodeficiency virus (HIV)infected patients has recently been recognised as part of HIV-associated neurocognitive
disorders. This has been implicated as one of the causes of poor adherence to antiretroviral
therapy (ART).
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Methods: This was a cross-sectional survey involving 218 participants consecutively sampled
from those attending the HIV treatment clinic at Aga Khan University Hospital in Nairobi.
Data collected included quantitative primary data on pre-defined baseline characteristics,
neurocognitive assessment by Montreal Cognitive Assessment (MoCA) tool (Appendix 1),
instrumental activities of daily living by Lawton score and objective and subjective adherence
measures by medication possession ratio (MPR) and simplified medication adherence
questionnaire (SMAQ) (see Appendix 2). Univariate and bivariate analyses were conducted to
determine the strengths of association between predictor and the outcome variables.
Results: Among the 218 participants in the study, a total of 69% had asymptomatic to mild
neurocognitive impairment as assessed by the MoCA tool, while a total of 66% were determined
as being adherent to ART by objective measures (by MPR) compared to subjective rates of
77% as assessed by SMAQ. However, no statistically significant association was observed
between the presence of asymptomatic or mild neurocognitive impairment and likelihood of
adherence to ART (p > 0.05).
Conclusion: Even though asymptomatic and mild forms of cognitive impairment are prevalent
in the population studied, there was no significant association between cognitive impairment
and adherence to treatment.

Introduction
Human immunodeficiency virus (HIV) is associated with neurological complications, including
neurocognitive impairment. The early screening neuropsychological tests were designed to assess
cortical functions.1,2
The widely used screening tests, such as the International HIV Dementia Scale (IHDS), mainly
assess cortical function and are not sensitive to the milder forms of neurocognitive impairment.
HIV-associated neurocognitive disorder (HAND) has, however, been shown to mainly affect
subcortical functions.3
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code with your
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mobile device
to read online.

Adherence is one of the major determinants of successful viral suppression among people living
with HIV (PLWHIV) on antiretroviral therapy (ART).4 Mbugua found out that in the HIV-positive
patients attending the HIV clinic, 52% of the patients had an adherence rate of 95% or more, while
48% had suboptimal adherence, which was defined as an adherence less than 95%.4 Advisory
documents indicate that an adherence rate of 95% is necessary for successful viral suppression.5,6
There are many causes of poor adherence, some of which are attributed to neurocognitive
impairment that may be asymptomatic or mild, and thus go clinically unrecognised if not assessed.3
The American Academy of Neurology (AAN) has identified two forms of HAND since 1991,
namely minor cognitive motor disorder (MCMD) and HIV-associated dementia (HAD).
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The HIV Neurobehavioral Research Centre (HNRC) modified
the criteria, to include an additional group, and these criteria
were adopted by the AAN in 2007.7 The modified criteria,
also known as the Frascati criteria, recognised the following
three conditions: asymptomatic neurocognitive impairment
(ANI), HIV-associated mild neurocognitive disorder (MND)
and HAD. The notable addition was ANI, as research has
shown a considerable number of HIV patients with clinically
demonstrable cognitive abnormality but no impairment of
function.7 Asymptomatic neurocognitive impairment refers
to the patients with acquired cognitive impairment in at least
two ability domains, but the impairment does not interfere
with everyday functioning. MND refers to acquired cognitive
impairment involving at least two ability domains, with mild
interference in daily functioning either by self-report or
observation by others. HIV-associated dementia refers
to marked acquired cognitive impairment with marked
interference in day-to-day functioning.7 ANI and MND are
the mild forms of HAND.

Literature review
Human immunodeficiency virus is a neurotropic infection
and invades the central nervous system from the time of
primary infection.8
The introduction of ART heralded a significant change in the
spectrum of HAND, with prevalence of HAD decreasing and
the prevalence of the milder forms of HAND increasing,
predominantly ANI. Therefore, relying on self-report, as was
the case previously, missed out this population.7
In a study carried out in Botswana among HIV-positive
patients attending HIV clinic to assess the neurocognitive
impairment, it was found that despite 97.5% of the patients
being on ART, 38% of the population had neurocognitive
impairment as assessed by the IHDS. According to this
study, more than one-third of the population studied had
neurocognitive impairment despite being on ART for more
than two years, and one of the reasons for this finding was
attributed to the likely poor adherence to ART.9
Another study carried out at Kenyatta National Hospital
(KNH) in 2011 utilised IHDS to assess cognitive function and
determined the prevalence of neurocognitive impairment in
HIV-positive patients to be 26%, of which 23% were not
on ART.10
A meta-analysis of studies on prevalence of HAND in HIVpositive patients on ART for more than six months (data
collected up to June 2012, and using the IHDS) in seven
countries in sub-Saharan Africa (Uganda, Zambia, Malawi,
Botswana, Nigeria, Cameroon and South Africa) concluded
that the prevalence of neurocognitive impairment was more
than 30%.11
The CNS HIV Antiretroviral Therapy Effects Research
(CHARTER) Study is a landmark longitudinal prospective
study that was carried out in the ART era and as illustrated
http://www.sajhivmed.org.za
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below, the most prevalent form of HAND was found to be
the ANI followed by MND.12
The IHDS has been shown to be effective in screening for
HAD; however, it is not accurate for screening for mild
cognitive impairment as it either over-reports or underreports impairment. The IHDS assesses only cortical function
and thus can miss out patients with subcortical dysfunction,
as in HAND. Over-reporting can be caused by human error
among people administering the IHDS. 13,14,15,16
The Montreal Cognitive Assessment (MoCA) tool used for
assessing subcortical function has shown promise in HIV
mild cognitive impairment.15,17 It is a 10-min test that is ideal
as a screening test.
The MoCA has been validated and widely used in many
countries, in non-HIV populations, to screen for milder
forms of cognitive impairment. With a cut-off less than 26 for
mild neurocognitive impairment, the sensitivity was 83%
and the specificity was 81%.18 However, in PLWHIV, different
authors used scores of either 26 or 27, based on their local
validation studies. Chan et al. used MoCA in a study where
a diagnosis of HAND was made in 22.7% of 132 HIV-positive
patients in Singapore. In the study, Chan stated that local
validation studies had a cut-off score of 26 or 27 out of 30,
even though the studies were still under peer review.17 In a
study carried out on 100 HIV-positive patients to screen for
neurocognitive impairment with the use of MoCA as a
screening tool, it was found to have a sensitivity of 85%,
specificity of 40%, negative predictive value of 48% and a
positive predictive value of 81%, with a cut-off score of < 26.19
Raising the cut-off point of the MoCA was shown to increase
sensitivity but reduce specificity.3,20 Making a diagnosis of
HAND according to Frascati criteria,7 which was adopted by
the AAN in 2007, requires the use of a neuropsychological
battery of tests, as well as comparison with normative data
from the population. The MoCA tool attempts to assess the
eight domains of cognition to help in screening of patients
who would then be referred to neuropsychologists for
definitive diagnosis. These domains include visuospatial or
executive functioning, naming, attention, concentration
and calculation, language, abstraction, delayed recall and
orientation. In this study, the MoCA was utilised for
screening for cognitive impairment, with a cut-off score less
than 26 defined as cognitive impairment.
The Lawton Instrumental Activities of Daily Living (IADL)
assesses the eight domains of functions and is most useful for
identifying how a person is functioning at the present time
(Appendix 3). These domains include the ability to use a
telephone, shop, do housekeeping, complete laundry work,
transport, and the responsibility for taking medication and to
handle finances. The validity was tested by determining its
correlations with four scales that measured assessment of
functional status and all correlations were found to be
significant at 0.01 or 0.05 level.21 The tool was also used by
Open Access
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Chan17 in evaluation of HAND in the population of 132
HIV-positive patients. High scores depict independence,
while low scores depict high levels of dependence.
The World Health Organization (WHO) recommends ART
adherence of > 95% to achieve the best treatment outcomes.5,6

Justification
The HIV prevalence in Kenya is 5.6% according to the Kenya
AIDS Indicator Survey of 2012 (KAIS 2012) report released in
2014.22 About 84.5% of HIV-positive patients who are eligible
for ART were on treatment according to the 2012 survey. The
adherence rates are still suboptimal as shown by a study
carried out at Aga Khan University Hospital in 2011, which
showed that only 52% of the population had adherence rates
above 95% despite 82% of the patients self-reporting an
adherence rate of more than 95%.4
Although there has been a decline in the incidence of HAD in
the ART era, the prevalence rate of HAND remains elevated.23
Cognitive assessment is not routinely assessed in our HIV
clinics and is also not recommended in current Kenyan
treatment guidelines.
Poor judgement, memory impairment and poor decisionmaking as components of cognition may lead to poor
adherence rates in HIV-positive patients who are on ART.24,25
One primary cause of treatment failure has been linked to
HIV resistance, related to suboptimal adherence rates to
ART.2 Cognitive impairment may lead to failure to maintain
a stable income-generating activity as well as poor decisionmaking in lifestyle choices, such as taking medication.3
Patients, who are HIV-positive with other comorbid
conditions, will be required to take several medications, and
compliance to these medications requires good cognition.
In patients with drug resistance requiring complex regimens
or those taking concurrent treatment for tuberculosis or
Pneumocystis jirovecii pneumonia, poor cognition may lead to
further treatment failure.
Early recognition of neurocognitive impairment will also
guide clinicians towards appropriate referrals and further
tests for patients as well as strengthening of adherence
counselling.
Knowledge of how neurocognitive impairment affects ART
adherence will therefore significantly contribute to guidelines
in dealing with this potential factor in improving outcomes
for PLWHIV.

Primary objective
To determine the association between the milder forms of
cognitive impairment (ANI and MND) and adherence to
ART in PLWHIV attending clinic at Aga Khan University
Hospital, Nairobi.
http://www.sajhivmed.org.za
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Methodology
Study design

The study is an analytical cross-sectional survey assessing
the association between mild cognitive impairment
(asymptomatic and MND) and adherence to treatment with
ART in HIV-positive patients.

Study setting and period
The study was carried out in the HIV clinic at Aga Khan
University Hospital (AKUHN), situated in Nairobi, Kenya.
About 635 HIV-positive patients are on follow-up at the
AKUHN’s infectious diseases clinics, out of which an
estimated 95% (603) are on treatment with ART (about
500 [83%] of them for at least six months, hence eligible for
this study). The study was conducted between October 2015
and May 2016, a period during which all those eligible for the
study visited the clinic at least once and had a chance to be
selected to participate.

Sample size calculation
The sample size for this study was derived using a sampling
formula for a finite population, with an error margin no
larger than 0.05.26 This is as shown below:
n=

m

m−1
1+
N

[Eqn 1]

where
m=

(

Zα2 / 2 p 1 − p
d2

)

[Eqn 2]

So that:
• Zα/2 = standard normal variate (1.96) for level of
significance (0.05);
• N = total number of population, which is 500;
• n = sample size;
• m = sample size necessary for estimating the prevalence
of the total population, N;
• d = error, 0.05;
• p = prevalence of non-adherence in HIV-positive patients
attending clinic, estimated at 48% from a previous study
conducted in the same population4;
•

m=

(

1.962 * 0.48 1 − 0.48
2

0.05

• Therefore, n =

)

(m = 383.54);

383.54
(n = 218 patients).
383.54 − 1
1+
500

Inclusion criteria
• ≥ 18 years of age and ≤ 65 years;
• HIV-positive on ART for over six months;
• Ability to read and write in English.
Open Access
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Exclusion criteria
• Patients with an opportunistic infection affecting the CNS
in the last 12 months or non-CNS infection in the last
three months, or known to have a mental illness such as
depression or schizophrenia or having epilepsy.
• History of current substance abuse.
• History of head injury with loss of consciousness
exceeding 30 min.

Sampling technique and data collection
Over the study period, a total of 635 patients attended the
clinics, of whom, 500 were eligible for the study.
Consecutive sampling was utilised, recruiting every eligible
clinic patient into the study as they visited the clinic during
this period, until the sample size was met.
The following is the recruitment procedure:
• HIV-positive patients were recruited from the HIV clinic
at AKUHN by the principal investigator during opening
hours (Monday to Saturday).
• Informed consent was obtained from the patients who
had met the eligibility criteria. The principal investigator
discussed the consent process with the patients in detail
and they were given a chance to decline participation.
• The patients were provided with a questionnaire to obtain
biographical data.
• The MoCA questionnaire was administered to patients
to assess for cognitive function, with a cut-off less
than 26.
• The patient’s functional status at work and at home was
assessed using the Lawton’s IADL tool, by self-reporting.
• Self-reported adherence to ART using the simplified
medication adherence questionnaire (SMAQ) tool was
also established.
• Medication possession ratio (MPR) was then calculated
based on the pharmacy dispensing records for about three –
eight months to assess their possession rate as an objective
measure of adherence using the following formula:
Pills dispensed/pills prescribed per day
× 100%. 
Number of days between refills

[Eqn 3]

The MPR is a validated, pharmacy-based method for
assessment of adherence in areas where pill count is not
normally done as is the case at the Aga Khan University
Hospital, Nairobi.27
For a diagnosis of HAND to be made, the Frascati criteria,
adopted by AAN, need to be met; however, for screening
purposes, normal cognition is any score of 26 and above.
The MoCA cannot distinguish between HAD and minor
forms of neurocognitive impairment. However, as per the
Frascati criteria, low cognitive scores, together with
increased dependence on others for IADL, would give a
diagnosis of HAD.7
http://www.sajhivmed.org.za
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Optimal adherence was defined as 95% and above, as per the
WHO’s recommendations, with suboptimal adherence being
any value less than 95%.5,6 The MPR was calculated for each
patient based on the pharmacy dispensing records, for at
least three months.
The SMAQ was utilised for assessment of self-reported
adherence for comparison with the MPR, and it has been
validated for use in the HIV-positive population, with a
sensitivity of 72% and a specificity of 91%.28,29

Data analysis
This study utilised a quantitative design involving collection
and analysis of quantitative primary data about pre-defined
variables. Additional data were also collected on other
patient-specific attributes that are likely to affect adherence
patterns.
Descriptive statistics were used to summarise the data
including frequency tables for demographic characteristics of
the participants. Other baseline characteristics related to the
participants’ HIV treatment were also analysed.
The patients were then grouped based on their neurocognitive
status (with and without impairment).
Other baseline factors with potential to affect adherence in
the two patient groups were also compared. Thereafter,
bivariate analysis using chi-square test was used to test the
relationship between individual predictor and outcome
variables. The choice of chi-square test in this regard is
especially suited to conducting hypothesis tests for
categorical data such as that used for this study.
Data collected, collated and cleaned in Excel worksheets
were eventually analysed using Statistical Package for Social
Sciences (SPSS) version 21.

Ethical consideration
The study was carried out with approval from the Department
of Internal Medicine, AKUHN and the Ethical and Scientific
Review Committee. Informed written consent was obtained
from all participants.

Results
A total of 500 patients were found to be eligible for the study.
A final sample size of 218 patients was recruited to participate
in the study. For those not eligible, the main reasons for
ineligibility were duration on ART of less than six months,
presence of space occupying lesions and other central
nervous system abnormalities, and extremes of age above
65 years. No patients were found to have HAD, 69%
had minor neurocognitive dysfunction and 31% had no
neurocognitive dysfunction. Those selected underwent
adherence assessment. The overall optimal adherence rate
for this population was 66% by objective assessment (MPR)
and 77% by subjective assessment (SMAQ).
Open Access
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Summary of baseline characteristics
Of the 218 participants selected for the study, a total of
215 completed the MoCA neurocognitive assessment.
The study population varied according to different baseline
demographic and HIV treatment-related characteristics
(Tables 1 and 2).
Those with normal neurocognitive function had a mean age
of 42.3 years, while the mean age for those with impaired
cognitive function was 45.5 years.
The source of a patient’s medicine was thought to be
important, as it determined the availability of the medicine
TABLE 1: Baseline demographic characteristics.
Baseline
characteristic

Variable

Overall outcome

-

Age
Gender
Education level

Marital status

Living with family
Employment status

Level of income (US
dollars per month)

MoCA neurocognitive assessment score
Normal

%

Impaired

%

67

31

147

69

Mean

42.3 years

-

45.5 years

-

Male

34

51

67

46

Female

33

49

80

54

Primary

1

2

11

8

Secondary

9

13

29

20

Tertiary

57

85

106

73

Married

37

55

101

69

Widowed

11

16

14

10

Divorced or
separated

4

6

10

7

Single

15

22

21

14

Yes

57

85

127

86

No

10

15

20

14

Employed

48

72

96

66

Self-employed

15

22

40

27

Unemployed

4

6

10

7

0–100

5

8

22

15

110–500

12

19

46

32

510–1000

20

32

31

22

> 1000

26

41

45

32

MoCA, Montreal Cognitive Assessment.

TABLE 2: Human immunodeficiency virus treatment-related characteristics.
Characteristic

Variable

MoCA score
Normal

Normal
(%)

Impaired

Impaired
(%)

Duration since HIV Mean
diagnosis (years)

7.6 years

-

8.0 years

-

Duration on ART
(years)

Mean

5.47 years

-

6.69 years

-

Source of ART
medicines

AKUHN

57

85

128

88

Other

10

15

18

12

Payment for
medication

Cash

18

27

41

28

Insurance

43

64

95

65

Insurance/cash

1

1

5

3

ART regimen

First viral load
Latest viral load

Free

5

7

5

3

EFV-based

48

72

98

70

PI-based

11

16

32

23

Other

8

12

10

7

Suppressed

51

88

103

82

Not suppressed

7

12

22

18

Suppressed

41

68

84

67

Not suppressed

19

32

42

33

AKUHN, Aga Khan University Hospital, Nairobi; ART, antiretroviral therapy; HIV, human
immunodeficiency virus; MoCA, Montreal Cognitive Assessment; EFV, Efavirenz; PI, Protease
Inhibitor.
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and therefore adherence to treatment plans. This factor also
determined how many patients could be assessed objectively
by MPR owing to availability of pharmacy records. Similarly,
income and therefore ability to afford medication was
important, as it related to adherence to treatment and
outcomes thereafter.

Bivariate analysis: Cognitive impairment and adherence
to antiretroviral therapy (as measured by medication
possession ratio)
A bivariate analysis was conducted to determine the existence
of any significant association between the presence of mild
cognitive impairment as measured by the MoCA score and
the ability to adhere to prescribed treatment with ART as
measured objectively through calculation of the MPR. The
results showed a lack of significant association (p = 0.490)
between the two variables (Table 3).

Bivariate analysis: Cognitive impairment and adherence
to antiretroviral therapy (as measured by simplified
medical adherence questionnaire)
A bivariate analysis was conducted to determine the existence
of any significant association between the presence of mild
cognitive impairment as measured by the MoCA score and
the ability to adhere to prescribed treatment with ART as
measured subjectively through the SMAQ questionnaire. The
results showed a lack of significant association (p = 0.658)
between the two variables (Table 4).

Secondary analysis
Secondary analysis was conducted for any association
between baseline patient characteristics and the observed
adherence patterns; as such, characteristics could serve as
confounders to the outcome variable. Table 5 shows the
outcomes of the bivariate analysis between selected
baseline characteristics of participants and the adherence
patterns as assessed objectively by MPR and subjectively
by SMAQ.
The numbers do not consistently add up owing to some
missing data. An example is MPR calculation owing to
patients collecting their medication from outside the
hospital.
TABLE 3: Bivariate analysis of Montreal Cognitive Assessment scores and
Medication Possession Ratio.
Neurocognitive
assessment

Variable

Adherence by MPR

p

Optimal (number Suboptimal (number
of participants)
of participants)

MoCA neurocognitive Normal
assessment score
Impaired

34

15

74

42

0.490

MPR, medication possession ratio; MoCA, Montreal Cognitive Assessment.

TABLE 4: Bivariate analysis of Montreal Cognitive Assessment and simplified
medication adherence questionnaire.
Neurocognitive
assessment

Variable

MoCA
Normal
neurocognitive
assessment score Impaired

Adherence by SMAQ

p

Adherent
Non-adherent
(no. of participants) (no. of participants)
50

17

113

33

0.658

MoCA, Montreal Cognitive Assessment; SMAQ, simplified medication adherence questionnaire.
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TABLE 5: Bivariate analysis for baseline characteristics and adherence.
Variable

Category

Sex
Education level

Marital status

Living with family
Employment status

Payment mode

Adherence by MPR (no. of participants)

Adherence by SMAQ (no. of participants)

Optimal

Suboptimal

p

Adherent

Non-adherent

p

Male

55

28

0.870

78

22

0.633

Female

54

29

85

28

Primary

8

2

9

3

Secondary

24

10

30

8

Tertiary

77

45

123

39

Married

72

39

112

26

Widowed

10

7

19

6

Divorced or separated

8

3

8

6

Single

18

8

23

12

Yes

91

51

143

41

No

18

6

20

9

Employed

75

33

115

28

Self-Employed

27

20

39

16

Unemployed

7

4

Cash

30

19

Insurance

75

Free
Insurance or cash
Source of medicines AKUHN
Other

0.443

0.857

0.298
0.348

8

6

46

13

35

106

31

2

0

7

3

1

3

4

2

104

55

141

43

4

2

21

7

0.195

0.949

0.918

0.077

0.301
0.079

0.879

0.850

MPR, medication possession ratio; SMAQ, simplified medication adherence questionnaire.

TABLE 6: Bivariate analysis with use of the latest viral load as a measure of
adherence.
MoCA score
assessment

p

Latest viral load
Viral load suppressed
(< 1000 copies/mL)

Viral load not suppressed
(> 1000 copies/mL)

Normal

57

3

Impaired

115

13

Unknown

30

-

0.238

MoCA, Montreal Cognitive Assessment.

As shown in Table 5, there was no statistically significant
association between any baseline patient characteristics and
adherence by either MPR or SMAQ (all p-values were > 0.05).
A sub-analysis was conducted to determine the association
between the measures of cognitive impairment using MoCA
and the latest viral load as a surrogate measure of adherence.
With a cut-off of 1000 copies per millilitre (mL), patients with
a viral load greater than 1000 copies/mL were considered not
suppressed and therefore non-adherent to ART, while
patients with a viral load less than 1000 copies/mL were
considered to have a suppressed viral load and therefore
adherent to ART.30 There was no significant association
between the presence of cognitive impairment and the
treatment outcomes as measured by viral load (p = 0.238)
(Table 6).

Discussion of findings
The study was carried out among patients attending the
clinic who are on follow-up, and as far as activities of daily
living assessment were concerned, they were independent.
The population studied had a mean age of 46.5 years in males
and 42.7 years in females. This is an older age group as
compared with the national statistics according to KAIS,
2012, which shows that HIV prevalence is the highest among
women aged 30–39 years.22 However, among the males, it is
http://www.sajhivmed.org.za

in line with the national statistics which show the highest
prevalence between 45 and 49 years of age.
The rate of cognitive impairment in this group is high, which
corresponds to some of the studies carried out, such as the
CHARTER study, which showed a 52% prevalence of
HANDs, with majority being asymptomatic and mild
cognitive disorders, and only 2% of this population having
HAD. On exclusion of patients with severe confounding
comorbidities, 46.9% of the remaining patients received a
diagnosis of HAND, and 70% of this population had ANI.12
In the current study, there was no patient presumably
identified to have HAD, as assessed by both MoCA and
Lawton score. One patient reported that she was independent
in IADL, even though she had a low MoCA score of 9/30.
The high prevalence of cognitive impairment in this group
could be because of several factors such as the MoCA, though
validated in other countries, being not wholly culturally
appropriate in our circumstances. Most participants had
difficulty recalling some unfamiliar items such as daisy,
velvet and the word couch, as part of the statement in the
language section, which were words that needed to be
assessed as part of cognitive assessment. This was also seen
in a study by Robbins et al., which was carried out in South
Africa among Xhosa-speaking people. They had to translate
the MoCA to the Xhosa language as well as modify it for the
tool to be culturally acceptable.3
The MoCA screening tool was initially designed to screen for
mild cognitive impairment by Nasreddine et al. and the cutoff score was set at less than 26.18 However, several validation
studies in the HIV setting have used different cut-off scores.
This could account for the classification of patients as having
normal versus impaired cognition, based on the cut-off score
set. In settings where a complete neurophysiological battery
Open Access
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of tests cannot be done readily, MoCA is a good screening
tool with high enough sensitivity in milder forms of cognitive
impairment.
The respondents were recruited during clinic hours in the
morning. Most of the patients were employed and as they
were coming in the routine clinic time, they were either
coming from work – night duty, or on their way to work. The
sense of spending more time than their usual clinic hours
seemed to be a factor in some of their performances, as some
patients reported that they were going to be late, were tired
and could therefore not concentrate well or were not in the
best state of mind to respond to the questions. It is postulated
that this could be one of the factors contributing to the
high prevalence rate of cognitive impairment. Cognitive
assessment is ideally a continuous process. The MoCA tool is
designed for screening for cognitive impairment, but
definitive diagnosis is done by a neurophysiologic battery of
tests, such as the HNRC battery of tests. It would be necessary
to carry out the tests several times and get an average score;
however, as this was a cross-sectional survey, we only relied
on one meeting with the patient to make our assessment. The
study design also limited the extent to which causality could
be established. The study was also limited by lack of data for
patients who obtained their medication or did their laboratory
tests outside the hospital.
According to this study, the adherence rate, calculated by
MPR, was 66%, compared with 77% as per subjective testing.
These results are comparable to a study conducted in
AKUHN, Kenya.4
Our study had several strengths. This is the first study, to our
knowledge, that has been carried out in Kenya, using MoCA
as a screening tool for cognitive impairment and associating
it with adherence to ART. It therefore gives a prevalence of
asymptomatic and mild cognitive impairment in this
population, whereas previous studies assessed prevalence of
HAND in general, and did not focus on the mild forms of
cognitive impairment. The earlier studies also used IHDS
and MMSE, which have been found to be less sensitive for
subcortical dysfunction that is more dominant in the mild
forms of HAND.
The sample size of 218, for a finite population of 500 eligible
patients, was adequate for assessment of the association
between milder forms of cognitive impairment and adherence
to ART; hence, the results may be generalisable in similar
settings but should be extrapolated to other populations with
caution because of the specific characteristics of the
population studied.
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Appendix 1

FIGURE 1-A1: Montreal Cognitive Assessment (MoCA).
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Appendix 2
Monitoring/esmang adherence to art in general
(Knobel et al. 2002)
1. Do you ever forget to take your medicine?

Yes

2. Are you careless at mes about taking your medicine?

Yes

No
No

3. Somemes if you feel worse, do you stop taking your
medicines?

Yes

No

4. Thinking about the last week. How oen have you not taken your
medicine?
Never
1 ± 2 mes
3 ± 5 mes
6 ± 10 mes
> 10 mes
5. Did you not take any of your medicine over the
past weekend?

Yes

No

6. Over the past 3 months, how many days have you not
taken any medicine at all?
≤ 2 days
> 2 days
SCORING: A positive response to any of the qualitative questions, more
than two doses missed over the past week, or over two days of total
non-medication during the past three months = non-adherent
(Knobel et al. 2002).

FIGURE 1-A2: Simplified Medication Adherence Questionnaire (SMAQ)

Appendix 3
Lawton’s instrumental activities of daily living
Date:

Name

Please check the box that most applies for each activity:
Activity

Need no help
(2 pts. each)

Need some help
(1 pt. each)

Unable to do at all
(0 pts. each)

1. Using the
telephone

___

___

___

2. Getting to places
beyond walking
distance

___

___

___

3. Grocery shopping

___

___

___

4. Preparing meals

___

___

___

5. Doing housework
or handyman work

___

___

___

6. Doing laundry

___

___

___

7. Taking
medications

___

___

___

___

___

___

(___ x 2 =) ___ +

(___ x 1=) ___ +

0

8. Managing money
Total Score: ___ =

Source: Lawton and Brody.21 Copyright (c) by The Gerontological Society of America. Used by
permission of the Publisher.
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